Evidence map›Paper›PMID 31434983›Full record

ArticleScientific reports2019

Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.

Soudabeh Rad Pour, Hiromasa Morikawa, Narsis A Kiani, Muyi Yang, Alireza Azimi, Gowhar Shafi, Mingmei Shang, Roland Baumgartner, Daniel F J Ketelhuth, Muhammad Anas Kamleh and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Metabolic Cross Talk in the Tumor Microenvironment.Cancer treatment and research · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Soudabeh Rad PourUnit of Computational Medicine, Department of Medicine, Centre for Molecular Medicine, Karolinska Institute, SE-171 76, Stockholm, Sweden. soudabeh.rad-pour@ki.se.ORCID http://orcid.org/0000-0002-8114-7041
Hiromasa MorikawaBiological and Environmental Sciences and Engineering Division (BESE), Computer, Electrical, and Mathematical Sciences and Engineering Division (CEMSE), King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia.
Narsis A KianiUnit of Computational Medicine, Department of Medicine, Centre for Molecular Medicine, Karolinska Institute, SE-171 76, Stockholm, Sweden.
Muyi YangDepartment of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
Alireza AzimiDepartment of Immunology, Genetics & Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Gowhar ShafiDepartment of Genomics and Bioinformatics, Positive Bioscience, Mumbai, -400 002, India.
Mingmei ShangUnit of Computational Medicine, Department of Medicine, Centre for Molecular Medicine, Karolinska Institute, SE-171 76, Stockholm, Sweden.
Roland BaumgartnerExperimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Centre for Molecular Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Daniel F J KetelhuthExperimental Cardiovascular Research Group, Cardiovascular Medicine Unit, Centre for Molecular Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0087-116X
Muhammad Anas KamlehDivision of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77, Stockholm, Sweden.
Craig E WheelockDivision of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-8113-0653
Andreas LundqvistDepartment of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
Johan HanssonDepartment of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden.
Jesper TegnérUnit of Computational Medicine, Department of Medicine, Centre for Molecular Medicine, Karolinska Institute, SE-171 76, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEKing Abdullah University of Science and Technology · SAScience for Life Laboratory · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kynurenine pathway (KP) activation by the enzymatic activity of indoleamine 2,3-dioxygenase1 (IDO1) and kynurenine (KYN) production represents an attractive target for reducing tumour progression and improving anti-tumour immunity in multiple cancers. However, immunomodulatory properties of other KP metabolites such as 3-hydroxy kynurenine (3-HK) and kynurenic acid (KYNA) are poorly understood. The association of the kynurenine metabolic pathway with T-cell status in the tumour microenvironment were characterized, using gene expression data of 368 cutaneous skin melanoma (SKCM) patients from the TCGA cohort. Based on the identified correlations, we characterized the production of KYN, 3-HK, and KYNA in vitro using melanoma-derived cell lines and primary CD4+ CD25- T-cells. Activation of the CD4+ T-cells produced IFNγ, which yielded increased levels of KYN and KYNA. Concurrently, kynurenine 3-monooxygenase (KMO) expression and proliferation of CD4+ T-cells were reduced, whereas exhaustion markers such as PD-L1, AHR, FOXP3, and CTLA4 were increased. Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity. Our results suggest that, in addition to IDO1, there is an alternative immune regulatory mechanism associated with the lower KMO expression and the higher KYNA production, which contributes to dysfunctional effector CD4+ T-cell response.

Indexed as

B7-H1 AntigenCD4-Positive T-LymphocytesCell LineCell ProliferationCoculture TechniquesCulture Media, ConditionedCutaneous Malignant MelanomaForkhead Transcription FactorsGene Expression RegulationHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaKynurenic AcidKynurenineMelanomaMetabolic Networks and PathwaysB7-H1 AntigenBRAF protein, humanCD274 protein, humanCulture Media, ConditionedForkhead Transcription FactorsFOXP3 protein, humanIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaKynurenic AcidKynurenineProto-Oncogene Proteins B-rafTryptophan

Identifiers

PMID31434983
PMCPMC6704156
OpenAlexW2969552825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.